[
  {
    "ts": null,
    "headline": "ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth",
    "summary": "AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.",
    "url": "https://finnhub.io/api/news?id=a7b2ccc1f9ade8de00401e0212298710d33b7bd95149a5b22a9b9be9139c8f8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755866580,
      "headline": "ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth",
      "id": 136476664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.",
      "url": "https://finnhub.io/api/news?id=a7b2ccc1f9ade8de00401e0212298710d33b7bd95149a5b22a9b9be9139c8f8d"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: Strong Dividend Grower Made Even Better With Writing Options",
    "summary": "Read how we use the option wheel on SCHD for providing more consistent 'income' every month, along with our core long position that sits back and collects the dividend passively.",
    "url": "https://finnhub.io/api/news?id=0155f08f5cd2ddac3b63606ae8deb8e0912b31455397ba1d18b05a76c24db8ef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755861875,
      "headline": "SCHD: Strong Dividend Grower Made Even Better With Writing Options",
      "id": 136477090,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301983584/image_1301983584.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Read how we use the option wheel on SCHD for providing more consistent 'income' every month, along with our core long position that sits back and collects the dividend passively.",
      "url": "https://finnhub.io/api/news?id=0155f08f5cd2ddac3b63606ae8deb8e0912b31455397ba1d18b05a76c24db8ef"
    }
  },
  {
    "ts": null,
    "headline": "FDA Breakthrough for Lung Cancer Drug Might Change the Case For Investing In Merck (MRK)",
    "summary": "Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This marks the first Breakthrough Therapy Designation for ifinatamab deruxtecan and highlights the significance of the Merck-Daiichi Sankyo collaboration in developing potential first-in-class targeted cancer therapies. We'll...",
    "url": "https://finnhub.io/api/news?id=7119b0c7cd40ba3e62792d5c27c8fd2236aaa8e4ab1998c864da7055d5d6494b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755857632,
      "headline": "FDA Breakthrough for Lung Cancer Drug Might Change the Case For Investing In Merck (MRK)",
      "id": 136476724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This marks the first Breakthrough Therapy Designation for ifinatamab deruxtecan and highlights the significance of the Merck-Daiichi Sankyo collaboration in developing potential first-in-class targeted cancer therapies. We'll...",
      "url": "https://finnhub.io/api/news?id=7119b0c7cd40ba3e62792d5c27c8fd2236aaa8e4ab1998c864da7055d5d6494b"
    }
  },
  {
    "ts": null,
    "headline": "Dow up 380 points on gains for shares of Boeing, Honeywell",
    "summary": "Dow up 380 points on gains for shares of Boeing, Honeywell",
    "url": "https://finnhub.io/api/news?id=28391cbd604e6a8c52df6f32894cf9f62127055c92f7c8b53d16cbae33522288",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755855900,
      "headline": "Dow up 380 points on gains for shares of Boeing, Honeywell",
      "id": 136488801,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow up 380 points on gains for shares of Boeing, Honeywell",
      "url": "https://finnhub.io/api/news?id=28391cbd604e6a8c52df6f32894cf9f62127055c92f7c8b53d16cbae33522288"
    }
  }
]